Baidu
map

Blood:腹部血栓可能指向癌症

2015-06-24 佚名 生物谷

在美国血液协会杂志Blood上最新网上发表的一篇新研究中,研究人员表示腹壁下静脉的血凝块可能是癌症确诊的指标。这项研究还表明,这些凝块的存在预示肝癌和胰脏癌预后生存较差。 相比于普通人群,出现大腿深静脉血栓(DVT)或肺栓塞(PE)的个人可能在未来一年内被诊断患有癌症的机率高出了2到4倍。因为癌症的存在,使血液能够更容易凝结。不断扩大的肿瘤可压迫静脉,降低或减少血流量。在其他情况下,外

在美国血液协会杂志Blood上最新网上发表的一篇新研究中,研究人员表示腹壁下静脉的血凝块可能是癌症确诊的指标。这项研究还表明,这些凝块的存在预示肝癌和胰脏癌预后生存较差。


相比于普通人群,出现大腿深静脉血栓(DVT)或肺栓塞(PE)的个人可能在未来一年内被诊断患有癌症的机率高出了2到4倍。因为癌症的存在,使血液能够更容易凝结。不断扩大的肿瘤可压迫静脉,降低或减少血流量。在其他情况下,外科手术,炎症或肿瘤生长会损伤血管,促进凝血。

虽然很多人知道DVT、PE,和随后的癌症诊断之间的关系,却很少有人知道一些运输血液到肝脏或者其他腹腔器官的静脉的血栓怎么能充当癌症标记。这些血块,称为内脏静脉血栓(splanchnic venous thrombosis, SVT),是罕见的,而且通常存在于疾病的并发症。

为了更好地理解SVT是否可能指向未确诊的癌症,研究人员分析了1994-2011年间1000多名丹麦腹部静脉血栓确诊患者的出院诊断。研究人员跟踪随访了1191位患者平均1.6年,计算其后续的癌症诊断风险,与相比丹麦普通人口的预期风险相比。研究人员还评估了有SVT患者与无SVT癌症患者的生存预后。

研究者观察到,1191例患者有183位后来被诊断出患有癌症,并且超过一半(N=95)的癌症的诊断是在SVT发生后三个月内。大多数这些癌症发生在肝脏、胰腺或血液。比较SVT患者伴癌症和丹麦国家癌症发病率后,研究者表示,患者出现SVT在三个月内被诊断出癌症的概率比预期高出了33倍。

为了理解SVT如何影响那些癌症患者的生存预后,该研究小组比较这些患者与匹配队列的没有血块的肿瘤患者的预后。虽然无关SVT,肝脏或胰癌预后较差,但是SVT癌症患者三个月的生存率比无血栓的患者差很多。虽然研究人员没有观察到血液癌症患者在有无SVT情况下生存率的显著差异,但他们指出SVT诊断后超过12个月骨髓增殖性肿瘤的发病率较高。

“这项研究是首次在大范围的人口中调查内脏静脉血栓患者在相对较短的时间内被诊断出癌症,”Sogaard博士,本文的作者说道,“随着我们继续了解更多的SVT病人,将会了解SVT作为筛选隐藏癌症的利弊。”

原始出处:

Kirstine K. Søgaard*, Dóra K. Farkas, Lars Pedersen, and Henrik T. Sørensen.Splanchnic venous thrombosis is a marker of cancer and a prognostic factor for cancer survival.Blood, June 18, 2015.DOI: http://dx.doi.org/10.1182/blood-2015-03-631119

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=29119, encodeId=eb522911994, content=看看, beContent=null, objectType=article, channel=null, level=null, likeNumber=149, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee0d1618732, createdName=huaxipanxing, createdTime=Thu Jun 25 22:15:00 CST 2015, time=2015-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=29048, encodeId=21512904876, content=好文章, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=19691629579, createdName=zm0805, createdTime=Thu Jun 25 19:20:00 CST 2015, time=2015-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=28815, encodeId=11f72881552, content=多注意, beContent=null, objectType=article, channel=null, level=null, likeNumber=130, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ded71629504, createdName=nizongzan, createdTime=Thu Jun 25 09:31:00 CST 2015, time=2015-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=28723, encodeId=027828e23de, content=好文章。, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2018/12/08/243443e30b0c70a9384d25712f22dd6a.jpg, createdBy=f2db1629457, createdName=fujianmu, createdTime=Wed Jun 24 20:23:00 CST 2015, time=2015-06-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=28700, encodeId=d9d328e0072, content=学习了,知识面广, beContent=null, objectType=article, channel=null, level=null, likeNumber=129, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2be01625436, createdName=fatalmelanie, createdTime=Wed Jun 24 11:20:00 CST 2015, time=2015-06-24, status=1, ipAttribution=)]
    2015-06-25 huaxipanxing

    看看

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=29119, encodeId=eb522911994, content=看看, beContent=null, objectType=article, channel=null, level=null, likeNumber=149, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee0d1618732, createdName=huaxipanxing, createdTime=Thu Jun 25 22:15:00 CST 2015, time=2015-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=29048, encodeId=21512904876, content=好文章, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=19691629579, createdName=zm0805, createdTime=Thu Jun 25 19:20:00 CST 2015, time=2015-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=28815, encodeId=11f72881552, content=多注意, beContent=null, objectType=article, channel=null, level=null, likeNumber=130, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ded71629504, createdName=nizongzan, createdTime=Thu Jun 25 09:31:00 CST 2015, time=2015-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=28723, encodeId=027828e23de, content=好文章。, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2018/12/08/243443e30b0c70a9384d25712f22dd6a.jpg, createdBy=f2db1629457, createdName=fujianmu, createdTime=Wed Jun 24 20:23:00 CST 2015, time=2015-06-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=28700, encodeId=d9d328e0072, content=学习了,知识面广, beContent=null, objectType=article, channel=null, level=null, likeNumber=129, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2be01625436, createdName=fatalmelanie, createdTime=Wed Jun 24 11:20:00 CST 2015, time=2015-06-24, status=1, ipAttribution=)]
    2015-06-25 zm0805

    好文章

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=29119, encodeId=eb522911994, content=看看, beContent=null, objectType=article, channel=null, level=null, likeNumber=149, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee0d1618732, createdName=huaxipanxing, createdTime=Thu Jun 25 22:15:00 CST 2015, time=2015-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=29048, encodeId=21512904876, content=好文章, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=19691629579, createdName=zm0805, createdTime=Thu Jun 25 19:20:00 CST 2015, time=2015-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=28815, encodeId=11f72881552, content=多注意, beContent=null, objectType=article, channel=null, level=null, likeNumber=130, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ded71629504, createdName=nizongzan, createdTime=Thu Jun 25 09:31:00 CST 2015, time=2015-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=28723, encodeId=027828e23de, content=好文章。, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2018/12/08/243443e30b0c70a9384d25712f22dd6a.jpg, createdBy=f2db1629457, createdName=fujianmu, createdTime=Wed Jun 24 20:23:00 CST 2015, time=2015-06-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=28700, encodeId=d9d328e0072, content=学习了,知识面广, beContent=null, objectType=article, channel=null, level=null, likeNumber=129, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2be01625436, createdName=fatalmelanie, createdTime=Wed Jun 24 11:20:00 CST 2015, time=2015-06-24, status=1, ipAttribution=)]
    2015-06-25 nizongzan

    多注意

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=29119, encodeId=eb522911994, content=看看, beContent=null, objectType=article, channel=null, level=null, likeNumber=149, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee0d1618732, createdName=huaxipanxing, createdTime=Thu Jun 25 22:15:00 CST 2015, time=2015-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=29048, encodeId=21512904876, content=好文章, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=19691629579, createdName=zm0805, createdTime=Thu Jun 25 19:20:00 CST 2015, time=2015-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=28815, encodeId=11f72881552, content=多注意, beContent=null, objectType=article, channel=null, level=null, likeNumber=130, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ded71629504, createdName=nizongzan, createdTime=Thu Jun 25 09:31:00 CST 2015, time=2015-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=28723, encodeId=027828e23de, content=好文章。, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2018/12/08/243443e30b0c70a9384d25712f22dd6a.jpg, createdBy=f2db1629457, createdName=fujianmu, createdTime=Wed Jun 24 20:23:00 CST 2015, time=2015-06-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=28700, encodeId=d9d328e0072, content=学习了,知识面广, beContent=null, objectType=article, channel=null, level=null, likeNumber=129, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2be01625436, createdName=fatalmelanie, createdTime=Wed Jun 24 11:20:00 CST 2015, time=2015-06-24, status=1, ipAttribution=)]
    2015-06-24 fujianmu

    好文章。

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=29119, encodeId=eb522911994, content=看看, beContent=null, objectType=article, channel=null, level=null, likeNumber=149, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee0d1618732, createdName=huaxipanxing, createdTime=Thu Jun 25 22:15:00 CST 2015, time=2015-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=29048, encodeId=21512904876, content=好文章, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=19691629579, createdName=zm0805, createdTime=Thu Jun 25 19:20:00 CST 2015, time=2015-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=28815, encodeId=11f72881552, content=多注意, beContent=null, objectType=article, channel=null, level=null, likeNumber=130, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ded71629504, createdName=nizongzan, createdTime=Thu Jun 25 09:31:00 CST 2015, time=2015-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=28723, encodeId=027828e23de, content=好文章。, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2018/12/08/243443e30b0c70a9384d25712f22dd6a.jpg, createdBy=f2db1629457, createdName=fujianmu, createdTime=Wed Jun 24 20:23:00 CST 2015, time=2015-06-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=28700, encodeId=d9d328e0072, content=学习了,知识面广, beContent=null, objectType=article, channel=null, level=null, likeNumber=129, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2be01625436, createdName=fatalmelanie, createdTime=Wed Jun 24 11:20:00 CST 2015, time=2015-06-24, status=1, ipAttribution=)]
    2015-06-24 fatalmelanie

    学习了,知识面广

    0

相关资讯

卒中探测器可快速鉴别出血性卒中和血栓所致的卒中

有关微波卒中探测(Strokefinder)头盔的初始临床研究结果证实,使用微波可快速、准确地对卒中患者进行诊断。相关科学文献于6月16日发表。文献指出,卒中探测器能比现行方法更早诊断,减少脑损伤的可能性。 在文献中,来自查尔姆斯理工大学的研究者们汇报了其去年完成的初始研究结果。这项研究包括45例患者,结果数据显示,这项技术可确实可对发生急性症状的患者进行鉴别诊断,分辨出血性卒中和血栓所致的

“血栓”危害超乎想象

血栓形成,即血凝块形成,可以阻塞动脉或静脉血流,可以发生在任何年龄、任何时间。血栓形成是全球前三位的致死性心血管病——心脏病、脑卒中和静脉血栓栓塞症(VTE)的共同发病机制。 一般来说,长期卧床、肢体制动、大手术或创伤后、晚期肿瘤或有明显VTE家族史等均是VTE的危险因素。如果出现下肢的突然疼痛、肿胀、活动后加重;有的可见小腿浅静脉的扩张或显露,严重者可伴有体温升高、心率加快,皮肤苍白甚至呈青紫

于波:冠脉血栓在影像学上的特点

急性心肌梗死(AMI)与急性冠脉综合征(ACS)都是以血栓事件为主的病理生理变化,二者都是从斑块的增生、加剧到斑块破裂形成血栓为基础。那么在临床实践中,血栓性病变我们应通过何种方式诊断?目前影像学有哪些进展,我们主要从血栓的形成以及目前对血栓评估的影像学的变化来进行探讨。 1  冠脉内血栓性病变的病理基础 急性心肌梗死(AMI)与急性冠脉综合征(ACS)有着共同的病理

ATVB:缺失蛋白或可抑制动脉硬化

近日,一项由Jason Johnson 博士领导的研究项目由英国心脏基金会资助(BHF),Jason Johnson 博士是布里斯托尔大学临床科学学院的高级研究员,相关文章发表在《动脉硬化、血栓和血管生物学》杂志上。 巨噬细胞对供给心脏血液的动脉是非常重要的,但动脉在给心脏供给血液的同时会累积脂肪,这一过程称为动脉粥样硬化。动脉粥样硬化病会导致动脉功能被削弱并且会使动脉管上产生裂纹,这样就

Eur Heart J: 房颤射频消融术后长期使用口服抗凝药有无必要?

射频消融术是对症状性房颤药物治疗无效情况下的推荐治疗方法,然而目前仍不能确定射频消融术和房颤相关的血栓栓塞并发症的降低有关联。欧洲心脏病学会(ESC)指南在对于房颤的管理上从2010年就推荐房颤患者在射频消融术后应持续系统性地口服抗凝药(OAC)治疗至少3个月,而是否持久性口服抗凝治疗应基于病人个体的脑卒中危险因素水平来决定(Ⅱa级推荐, C 级证据),显而易见,对于脑卒中高风险患者即使射频消融后

Baidu
map
Baidu
map
Baidu
map